Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 11, 2021

Effect of Cladribine on COVID-19 Serology Responses After BNT162b2 mRNA Vaccine in Patients With MS

Multiple Sclerosis and Related Disorders

 

Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis and Related Disorders
Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis
Mult Scler Relat Disord 2021 Oct 23;0(0)103343, L Brill, A Rechtman, O Zveik, et al

Further Reading